GemVax announced on the 30th that it is also considering the global technology transfer of its Alzheimer's disease treatment ‘GV1001’.
GemVax plans to secure stable funding through technology transfer to accelerate global clinical trials for ongoing domestic and international studies. It has completed approvals for Phase 2 clinical trials in the United States and seven European countries and is smoothly recruiting patients.
A GemVax representative stated, "We have received requests for data submission for the technology transfer of GV1001 from global big pharma companies," adding, "It is time to consider collaboration with global pharmaceutical companies to successfully lead overseas clinical trials and securely establish a global sales network."
GemVax’s global Phase 2 clinical trial is being conducted on patients with mild to moderate Alzheimer's disease following the FDA's proposal to expand indications. A total of 185 patients are being recruited, with 77 in the United States and 108 in Europe.
The GemVax representative said, "We are accelerating efforts to complete patient recruitment by the first half of next year."
The Phase 2 clinical trial of GV1001 for progressive supranuclear palsy (hereinafter PSP), being conducted domestically, is also progressing smoothly. The clinical trial plan (IND) was approved by the Ministry of Food and Drug Safety in March, and trials are underway at Seoul National University Hospital, Bundang Seoul National University Hospital, Boramae Medical Center, Samsung Medical Center, and Kyung Hee University Hospital.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
